A Study of Alegitazar in Patients With Type 2 Diabetes And Chronic Kidney Disease (Alerenal Study)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2013
This randomized, double-blind, placebo-controlled study will evaluate the potential of aleglitazar to reduce the risk of end stage renal disease and cardiovascular mortality in patients with type 2 diabetes mellitus and chronic kidney disease. Patients will be randomized to receive oral daily doses of aleglitazar or matching placebo. The anticipated time on study treatment is approximately 3 years.
Epistemonikos ID: 2c73d4c3adf12db8e85de35a665a3165885eb7b9
First added on: May 11, 2024